Becton, Dickinson Announced The Enrollment Of The First Patient In The Investigational Device Exemption Study, "AGILITY," Which Will Assess The Safety And Effectiveness Of The Bd Vascular Covered Stent For Peripheral Arterial Disease
Portfolio Pulse from Benzinga Newsdesk
Becton, Dickinson (BDX) has started the AGILITY clinical study to evaluate the safety and effectiveness of its BD Vascular Covered Stent for Peripheral Arterial Disease. The study will involve 315 patients across the US, Europe, Australia, and New Zealand, with follow-ups ranging from one month to 36 months.
March 04, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Becton, Dickinson's initiation of the AGILITY study for its Vascular Covered Stent could enhance its product portfolio and market position in treating Peripheral Arterial Disease.
The initiation of the AGILITY study by BDX is a critical step towards regulatory approval and commercialization of its Vascular Covered Stent for Peripheral Arterial Disease. Positive outcomes from this study could significantly enhance BDX's product portfolio and strengthen its position in the market. Given the study's global scale and the follow-up period, it demonstrates BDX's commitment to addressing Peripheral Arterial Disease, potentially leading to increased investor confidence and a positive impact on its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90